Phase II, Open-Label, Multicenter, Randomized Study of the Efficacy and Safety of Adjuvant Autogene Cevumeran Plus Atezolizumab and mFOLFIRINOX Versus mFOLFIRINOX Alone in Patients With Resected Pancreatic Ductal Adenocarcinoma
Summary
The purpose of this phase II trial is to evaluate the safety and efficacy of adjuvant autogene cevumeran plus atezolizumab and modified leucovorin, 5-fluorouracil (5-FU), irinotecan, and oxaliplatin (mFOLFIRINOX) versus mFOLFIRINOX alone in participants with resected pancreatic ductal adenocarcinoma (PDAC).
General Information
NCT#: NCT05968326
Study ID: GO44479
Trial Phase: Phase II
Trial Sponsor: Genentech
Therapies Used in This Trial: FOLFIRINOX, Atezolizumab, Autogene Cevumeran